Theralase Technologies Inc. V.TLT

Alternate Symbol(s): V.TLT.W | TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > 2022 AUA congress will be held May 13-16, 2022

<< Previous

Bullboard Posts

Next >>

Comment by enriquesuaveon Mar 10, 2022 5:55pm

160 Views

Post# 34504743

RE:RE:2022 AUA congress will be held May 13-16, 2022

Back in early January I had emailed management about applying for a late breaking presentation if possible as deadline was February 14 It all depends on Principal Investigator IMO If not this congress then maybe ASCO ?

Eoganacht wrote: 5 of our 12 principle investigators will be speaking - Drs. Kassouf, Black, Jayram, Shore and Richards and 2 of the 3 members of our MSAB - Drs. Kamat and O'Donnell. None of them are scheduled to speak about our trial but it might get mentioned.

ScienceFirst wrote: The 2022 AUA congress will be held May 13-16, 2022.

TLT once presented an abstract there in 2018 with the MSAB members (Dr. Kamat, Prof. Lilge, etc ...).

That could be our perfect timing now with the Ph. 2b data. Could we have an oral presentation also?

Late abstract dates:

Q. What are Late-Breaking Abstracts?
A. AUA’s late-breaking abstract policy allows the submission of late-breaking abstracts only for trials for which no preliminary data are available at the time of the standard abstract submission deadline (November 1, 2021). Late-breaking submission is not a mechanism to submit updated data when preliminary data are available by the standard abstract submission deadline, nor to provide an opportunity to revise and resubmit abstracts rejected during the standard submission period. The Late-Breaking Submission period opens on January 3, 2022 and closes on February 14, 2022.

Abstract Submission Site Closes
Monday, November 1, 2021

Late-breaking Abstract Submission Site Opens
Monday, January 3, 2022

Abstract Notifications Sent
Friday, January 7, 2022

Late-breaking Abstract Submission Site Closes
Monday, February 14, 2022